NO20062148L - Antistoffer som binder interleukin-4-reseptor - Google Patents
Antistoffer som binder interleukin-4-reseptorInfo
- Publication number
- NO20062148L NO20062148L NO20062148A NO20062148A NO20062148L NO 20062148 L NO20062148 L NO 20062148L NO 20062148 A NO20062148 A NO 20062148A NO 20062148 A NO20062148 A NO 20062148A NO 20062148 L NO20062148 L NO 20062148L
- Authority
- NO
- Norway
- Prior art keywords
- antibodies
- receptor
- muteins
- fragments
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Den foreliggende oppfinnelsen vedrører antistoffer som binder seg til IL-4 reseptoren, fragmenter, muteiner og derivater av slike antistoffer, nukleinsyrer som koder for slike antistoffer, fragmenter, muteiner og derivater og fremgangsmåter for å lage og anvende slike antistoffer, fragmenter, muteiner, derivater og nukleinsyrer. Fremgangsmåter for å behandle medisinske tilstander indusert ved interleukin-4 involverer å gi et IL-4 reseptorbindende antistoff eller et IL-4 reseptorbindende fragment, mutein eller derivat av et IL-4 reseptorbindende antistoff til en pasient som lider av slik tilstand. Bestemte antistoffer tilveiebrakt her inkluderer humane monoklonale antistoffer. Visse av antistoffene hemmer både IL-4 indusert og IL-13 induserte biologiske aktiviteter.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51816603P | 2003-11-07 | 2003-11-07 | |
PCT/US2004/037242 WO2005047331A2 (en) | 2003-11-07 | 2004-11-04 | Antibodies that bind interleukin-4 receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062148L true NO20062148L (no) | 2006-07-21 |
Family
ID=34590230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062148A NO20062148L (no) | 2003-11-07 | 2006-05-12 | Antistoffer som binder interleukin-4-reseptor |
Country Status (26)
Country | Link |
---|---|
US (4) | US20050112694A1 (no) |
EP (1) | EP1692184B1 (no) |
JP (1) | JP4931597B2 (no) |
KR (1) | KR101225463B1 (no) |
CN (1) | CN1886426A (no) |
AT (1) | ATE548388T1 (no) |
AU (1) | AU2004290017B2 (no) |
BR (1) | BRPI0416603A (no) |
CA (1) | CA2543982C (no) |
CR (1) | CR8396A (no) |
EA (1) | EA011302B1 (no) |
EC (1) | ECSP066526A (no) |
ES (1) | ES2383809T3 (no) |
GE (1) | GEP20104991B (no) |
IL (1) | IL175362A (no) |
IS (1) | IS8432A (no) |
MA (1) | MA28418B1 (no) |
MX (1) | MXPA06004853A (no) |
NI (1) | NI200600098A (no) |
NO (1) | NO20062148L (no) |
NZ (1) | NZ547588A (no) |
TN (1) | TNSN06128A1 (no) |
TW (1) | TWI356064B (no) |
UA (1) | UA93653C2 (no) |
WO (1) | WO2005047331A2 (no) |
ZA (1) | ZA200604605B (no) |
Families Citing this family (171)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE16192152T1 (de) | 2000-05-26 | 2020-08-06 | Immunex Corporation | Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
EA012801B1 (ru) | 2005-06-14 | 2009-12-30 | Эмджен Инк. | Самобуферирующиеся композиции белков |
CA2622016A1 (en) * | 2005-09-09 | 2007-03-15 | Imperial Innovations Limited | Interferon lambda therapy for treatment of respiratory diseases |
UA96139C2 (uk) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
PT2769992T (pt) | 2006-10-02 | 2021-03-11 | Regeneron Pharma | Anticorpos humanos com elevada afinidade para o receptor de il-4 humana |
DK2442107T3 (da) | 2006-11-01 | 2014-05-19 | Ventana Med Syst Inc | Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse |
US7682789B2 (en) * | 2007-05-04 | 2010-03-23 | Ventana Medical Systems, Inc. | Method for quantifying biomolecules conjugated to a nanoparticle |
ES2731432T3 (es) | 2007-05-23 | 2019-11-15 | Ventana Med Syst Inc | Transportadores poliméricos para inmunohistoquímica e hibridación in situ |
EP2197421A1 (en) * | 2007-08-31 | 2010-06-23 | Amgen, Inc | Solid-state protein formulation |
CA2698809C (en) | 2007-09-14 | 2023-10-17 | Amgen Inc. | Homogeneous antibody populations |
ES2750254T3 (es) | 2007-09-27 | 2020-03-25 | Amgen Inc | Formulaciones farmacéuticas |
EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
EP3381445B1 (en) | 2007-11-15 | 2023-10-25 | Amgen Inc. | Aqueous formulation of antibody stablised by antioxidants for parenteral administration |
CA2708871C (en) * | 2007-12-21 | 2017-11-21 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (il-4r.alpha.) - 173 |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
WO2009121847A2 (en) * | 2008-04-02 | 2009-10-08 | Apogenix Gmbh | Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders |
ES2557594T3 (es) | 2008-06-05 | 2016-01-27 | Ventana Medical Systems, Inc. | Método para el procesamiento histoquímico y el uso de una composición para el procesamiento histoquímico |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
MX344382B (es) | 2009-10-23 | 2016-12-14 | Amgen Inc * | Adaptador de vial y sistema. |
USPP22463P3 (en) * | 2010-02-16 | 2012-01-17 | Menachem Bornstein | Gypsophila plant named ‘Pearl Blossom’ |
CN110655573B (zh) * | 2010-02-26 | 2023-07-18 | 生命北极神经科学公司 | 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用 |
ES2545411T5 (es) | 2010-06-07 | 2024-04-05 | Amgen Inc | Dispositivo de administración de fármaco |
CN103097418A (zh) | 2010-07-09 | 2013-05-08 | 霍夫曼-拉罗奇有限公司 | 抗神经毡蛋白抗体及使用方法 |
US9480624B2 (en) | 2011-03-31 | 2016-11-01 | Amgen Inc. | Vial adapter and system |
LT2699293T (lt) | 2011-04-20 | 2019-04-25 | Amgen Inc. | Automatinio purškimo prietaisas |
US8846042B2 (en) | 2011-05-16 | 2014-09-30 | Fabion Pharmaceuticals, Inc. | Multi-specific FAB fusion proteins and methods of use |
EA028278B1 (ru) | 2011-09-16 | 2017-10-31 | Ридженерон Фармасьютикалз, Инк. | СПОСОБЫ СНИЖЕНИЯ УРОВНЕЙ ЛИПОПРОТЕИНА(а) ПОСРЕДСТВОМ ВВЕДЕНИЯ ИНГИБИТОРА ПРОПРОТЕИНКОНВЕРТАЗЫ СУБТИЛИЗИН/КЕКСИН-9 (PCSK9) |
KR102084171B1 (ko) | 2011-10-14 | 2020-04-14 | 암젠 인크 | 주사기 및 어셈블리 방법 |
BR112014022692A8 (pt) | 2012-03-14 | 2021-07-20 | Regeneron Pharma | molécula de ligação de antígeno multiespecífica |
US9574004B2 (en) | 2012-08-21 | 2017-02-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
SI3081249T1 (sl) | 2012-11-21 | 2021-03-31 | Amgen Inc. | Naprava za dajanje zdravila |
EP2970500A1 (en) | 2013-03-14 | 2016-01-20 | Bayer HealthCare LLC | Monoclonal antibodies against antithrombin beta complexed with heparin |
US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
TWI639449B (zh) | 2013-03-15 | 2018-11-01 | 美商安美基公司 | 用於注射器之匣盒 |
CA2904725C (en) | 2013-03-15 | 2022-04-12 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
WO2014149357A1 (en) | 2013-03-22 | 2014-09-25 | Amgen Inc. | Injector and method of assembly |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
PL3010539T3 (pl) | 2013-06-21 | 2020-01-31 | Sanofi Biotechnology | Sposoby leczenia polipowatości nosa przez podawanie antagonisty il-4r |
TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
AU2014318017B2 (en) | 2013-09-05 | 2020-02-06 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
AU2014340174B2 (en) | 2013-10-24 | 2019-09-12 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
US11097055B2 (en) | 2013-10-24 | 2021-08-24 | Amgen Inc. | Injector and method of assembly |
DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
CA2939506C (en) | 2014-02-28 | 2022-08-23 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an il-4r antagonist |
CN106413779B (zh) | 2014-05-07 | 2020-06-05 | 安姆根有限公司 | 具有减震元件的自助注射器 |
MX2016014761A (es) | 2014-05-16 | 2017-05-25 | Amgen Inc | Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2). |
JP6822843B2 (ja) | 2014-06-03 | 2021-01-27 | アムジエン・インコーポレーテツド | 薬物送達装置によって収集されたデータを遠隔で処理するためのシステム及び方法 |
WO2016023916A1 (en) | 2014-08-12 | 2016-02-18 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
PT3973987T (pt) | 2014-09-15 | 2024-04-01 | Regeneron Pharma | Combinação compreendendo um antagonista de il-4r, um corticoesteroide e um agonista beta2-adrenérgico de ação prolongada para tratar a asma |
EP3943135A3 (en) | 2014-10-14 | 2022-06-29 | Amgen Inc. | Drug injection device with visual and audible indicators |
WO2016071701A1 (en) | 2014-11-07 | 2016-05-12 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
CA2967602A1 (en) | 2014-11-14 | 2016-05-19 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
ES2785311T3 (es) | 2014-12-19 | 2020-10-06 | Amgen Inc | Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario |
US10799630B2 (en) | 2014-12-19 | 2020-10-13 | Amgen Inc. | Drug delivery device with proximity sensor |
EP3258988B1 (en) | 2015-02-17 | 2019-08-28 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
US11806509B2 (en) | 2015-02-27 | 2023-11-07 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement |
WO2017007796A1 (en) | 2015-07-06 | 2017-01-12 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
SI3334747T1 (sl) | 2015-08-13 | 2024-02-29 | Amgen Inc. | Globinsko nabito filtriranje proteinov, ki vežejo antigen |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
EP3386573B1 (en) | 2015-12-09 | 2019-10-02 | Amgen Inc. | Auto-injector with signaling cap |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
CA3014202A1 (en) | 2016-02-19 | 2017-08-24 | Regeneron Pharmaceuticals, Inc. | Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist |
EP4035711A1 (en) | 2016-03-15 | 2022-08-03 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
WO2017157305A1 (en) | 2016-03-15 | 2017-09-21 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
US11352446B2 (en) | 2016-04-28 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
US10988284B2 (en) | 2016-05-13 | 2021-04-27 | Amgen Inc. | Vial sleeve assembly |
US11238150B2 (en) | 2016-05-16 | 2022-02-01 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
WO2017209899A1 (en) | 2016-06-03 | 2017-12-07 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
CN113372446A (zh) | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
KR20240065318A (ko) | 2016-09-01 | 2024-05-14 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법 |
IL265516B2 (en) | 2016-09-22 | 2024-06-01 | Regeneron Pharma | Methods for treating severe allergic dermatitis by administering an il-4r inhibitor |
US10485844B2 (en) | 2016-09-22 | 2019-11-26 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor |
EP3528787A4 (en) | 2016-10-21 | 2020-05-06 | Amgen Inc. | PHARMACEUTICAL FORMULATIONS AND PROCESSES FOR THEIR PREPARATION |
EP3532127A1 (en) | 2016-10-25 | 2019-09-04 | Amgen Inc. | On-body injector |
TW202332696A (zh) | 2016-12-01 | 2023-08-16 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
EP3570917A1 (en) | 2017-01-17 | 2019-11-27 | Amgen Inc. | Injection devices and related methods of use and assembly |
CA3048520A1 (en) | 2017-02-17 | 2018-08-23 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
WO2018152073A1 (en) | 2017-02-17 | 2018-08-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
CA3050927A1 (en) | 2017-03-06 | 2018-09-13 | Brian Stonecipher | Drug delivery device with activation prevention feature |
KR102627069B1 (ko) | 2017-03-07 | 2024-01-18 | 암겐 인코포레이티드 | 과압에 의한 바늘 삽입 |
IL268386B2 (en) | 2017-03-09 | 2023-11-01 | Amgen Inc | Insertion mechanism for a drug delivery device |
MA47775A (fr) | 2017-03-14 | 2020-01-22 | Amgen Inc | Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire |
EP4241807A3 (en) | 2017-03-28 | 2023-10-11 | Amgen Inc. | Plunger rod and syringe assembly system and method |
EP3957752A3 (en) | 2017-04-13 | 2022-06-15 | Regeneron Pharmaceuticals, Inc. | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
JP7200134B2 (ja) | 2017-06-08 | 2023-01-06 | アムジエン・インコーポレーテツド | トルク駆動式薬物送達デバイス |
AU2018280054B2 (en) | 2017-06-08 | 2023-07-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
MX2019015472A (es) | 2017-06-22 | 2020-02-19 | Amgen Inc | Reduccion del impacto/choque de la activacion del mecanismo. |
AU2018290302B2 (en) | 2017-06-23 | 2024-02-29 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
WO2019014014A1 (en) | 2017-07-14 | 2019-01-17 | Amgen Inc. | NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM |
WO2019018169A1 (en) | 2017-07-21 | 2019-01-24 | Amgen Inc. | PERMEABLE GAS SEALING ELEMENT FOR MEDICINE CONTAINER AND METHODS OF ASSEMBLY |
EP4085942A1 (en) | 2017-07-25 | 2022-11-09 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
US11484648B2 (en) | 2017-07-25 | 2022-11-01 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
MA49838A (fr) | 2017-08-09 | 2020-06-17 | Amgen Inc | Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre |
EP3668567A1 (en) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
EP3691717B1 (en) | 2017-10-04 | 2023-02-08 | Amgen Inc. | Flow adapter for drug delivery device |
EP4257164A3 (en) | 2017-10-06 | 2024-01-17 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
IL273323B1 (en) | 2017-10-09 | 2024-06-01 | Amgen Inc | Drug delivery device with drive assembly and related assembly method |
CA3079946A1 (en) | 2017-10-30 | 2019-05-09 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
EP3703778A1 (en) | 2017-11-03 | 2020-09-09 | Amgen Inc. | System and approaches for sterilizing a drug delivery device |
EP3706830A1 (en) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Drug delivery device with placement and flow sensing |
EP3707075A1 (en) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Fill-finish assemblies and related methods |
CN111315413A (zh) | 2017-11-07 | 2020-06-19 | 秀比特生物技术公司 | 通过IgE类特异性免疫反应的抑制效果阻止婴儿期变态反应素质获得的方法 |
CN111225696B (zh) | 2017-11-10 | 2023-07-18 | 安进公司 | 用于药物递送装置的柱塞 |
AU2018368338A1 (en) | 2017-11-16 | 2020-04-09 | Amgen Inc. | Autoinjector with stall and end point detection |
AU2018368340B2 (en) | 2017-11-16 | 2024-03-07 | Amgen Inc. | Door latch mechanism for drug delivery device |
US11530259B2 (en) * | 2018-01-29 | 2022-12-20 | The Regents Of The University Of California | Therapies and methods to treat TLR2-mediated diseases and disorders |
RU2758092C1 (ru) * | 2018-02-01 | 2021-10-26 | Бэйцзин Кавин Текнолоджи Шеа-Холдинг Ко., Лтд. | АНТИТЕЛО К IL-4Rα И ЕГО ПРИМЕНЕНИЕ |
CN110105451B (zh) * | 2018-02-01 | 2020-12-18 | 北京凯因科技股份有限公司 | IL-4Rα抗体及其用途 |
MA52186A (fr) | 2018-03-26 | 2021-02-17 | Amgen Inc | Glycoformes afucosylées totales d'anticorps produits en culture cellulaire |
MX2020012064A (es) | 2018-05-13 | 2021-04-13 | Regeneron Pharma | Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r. |
CN113101364B (zh) * | 2018-05-29 | 2023-12-01 | 康诺亚生物医药科技(成都)有限公司 | 一种自免疫抑制剂的开发和应用 |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
US20210128844A1 (en) | 2018-07-24 | 2021-05-06 | Amgen Inc. | Delivery devices for administering drugs |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
EP3826701A1 (en) | 2018-07-24 | 2021-06-02 | Amgen Inc. | Delivery devices for administering drugs |
MA53320A (fr) | 2018-07-31 | 2021-11-03 | Amgen Inc | Ensemble de trajet de fluide pour dispositif d'administration de médicament |
CN110872349A (zh) * | 2018-09-04 | 2020-03-10 | 三生国健药业(上海)股份有限公司 | 结合人il-4r的抗体、其制备方法和用途 |
WO2020068623A1 (en) | 2018-09-24 | 2020-04-02 | Amgen Inc. | Interventional dosing systems and methods |
EP3856283A1 (en) | 2018-09-28 | 2021-08-04 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
AU2019352616A1 (en) | 2018-10-02 | 2021-03-18 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
TW202408605A (zh) | 2018-10-05 | 2024-03-01 | 美商安進公司 | 具有劑量指示器之藥物遞送裝置 |
CN117138169A (zh) | 2018-10-15 | 2023-12-01 | 安进公司 | 药物递送装置 |
US20210346596A1 (en) | 2018-10-15 | 2021-11-11 | Amgen Inc. | Platform assembly process for drug delivery device |
MA54057A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
WO2020091956A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
KR102330596B1 (ko) * | 2018-11-09 | 2021-11-26 | 아주대학교산학협력단 | 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도 |
CN111518211B (zh) | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 抗人白介素4受体α单克隆抗体的制药用途 |
MX2021010560A (es) | 2019-03-06 | 2021-11-12 | Regeneron Pharma | Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer. |
CN111686247B (zh) * | 2019-03-13 | 2022-07-29 | 苏州康乃德生物医药有限公司 | 包含人白介素-4受体α的抗体的液体组合物 |
KR20210143246A (ko) | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
US20220160972A1 (en) | 2019-04-24 | 2022-05-26 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
BR112022000581A2 (pt) | 2019-08-05 | 2022-03-03 | Regeneron Pharma | Métodos para tratamento de alergia e intensificação de imunoterapia específica dos alergénos através da administração de um antagonista de il-4r |
CA3147113A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
WO2021041067A2 (en) | 2019-08-23 | 2021-03-04 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
BR112022005583A2 (pt) | 2019-09-26 | 2022-09-20 | Amgen Inc | Métodos para a produção de composições de anticorpos |
CN115427450A (zh) | 2020-03-27 | 2022-12-02 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 |
CN113527485A (zh) | 2020-04-17 | 2021-10-22 | 上海麦济生物技术有限公司 | 抗人白细胞介素-4受体α抗体及其制备方法和应用 |
JP2023527775A (ja) | 2020-05-22 | 2023-06-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Il-4r阻害剤の投与により好酸球性食道炎を処置する方法 |
US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
CN117327181A (zh) * | 2020-06-22 | 2024-01-02 | 南京融捷康生物科技有限公司 | 抗IL-4Rα的单域抗体以及应用和药物 |
CA3197930A1 (en) | 2020-10-15 | 2022-04-21 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
AU2022206434A1 (en) | 2021-01-08 | 2023-08-24 | Regeneron Pharmaceuticals, Inc. | Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist |
KR20240011135A (ko) | 2021-05-21 | 2024-01-25 | 암젠 인크 | 약물 용기를 위한 충전 레시피를 최적화하는 방법 |
AU2022289365A1 (en) | 2021-06-07 | 2023-12-14 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
US20230167171A1 (en) | 2021-08-23 | 2023-06-01 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
AU2022361382A1 (en) | 2021-10-05 | 2024-03-28 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
WO2023085978A1 (en) * | 2021-11-11 | 2023-05-19 | Joint Stock Company «Biocad» | Monoclonal antibody or antigen-binding fragment thereof that specifically binds to il-4ra, and use thereof |
US20230220089A1 (en) | 2021-12-30 | 2023-07-13 | Regeneron Pharmaceuticals, Inc. | Methods for attenuating atopic march by administering an il-4/il-13 antagonist |
WO2023215750A2 (en) | 2022-05-02 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity |
TW202406572A (zh) | 2022-05-02 | 2024-02-16 | 美商再生元醫藥公司 | 抗介白素-4受體(il-4r)抗體調配物 |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
WO2024011251A1 (en) | 2022-07-08 | 2024-01-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist |
WO2024097714A1 (en) | 2022-11-01 | 2024-05-10 | Regeneron Pharmaceuticals, Inc. | Methods for treating hand and foot dermatitis by administering an il-4r antagonist |
WO2024112935A1 (en) | 2022-11-23 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Methods for improving bone growth by administering an il-4r antagonist |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005183A1 (en) * | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
SK279933B6 (sk) | 1989-12-20 | 1999-06-11 | Schering Corporation | Polypeptid, jeho subsekvencie a ich použitie |
EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
CA2157785A1 (en) | 1993-03-19 | 1994-09-29 | Immunex Corporation | Pharmaceutical compositions comprising soluble interleukin-4 receptor and interleukin-4 |
KR100654645B1 (ko) | 1995-04-27 | 2007-04-04 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
DE16192152T1 (de) * | 2000-05-26 | 2020-08-06 | Immunex Corporation | Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon |
-
2004
- 2004-11-04 AT AT04810551T patent/ATE548388T1/de active
- 2004-11-04 CA CA2543982A patent/CA2543982C/en not_active Expired - Fee Related
- 2004-11-04 UA UAA200606109A patent/UA93653C2/ru unknown
- 2004-11-04 CN CNA2004800354674A patent/CN1886426A/zh active Pending
- 2004-11-04 US US10/982,359 patent/US20050112694A1/en not_active Abandoned
- 2004-11-04 EP EP04810551A patent/EP1692184B1/en active Active
- 2004-11-04 BR BRPI0416603-5A patent/BRPI0416603A/pt not_active IP Right Cessation
- 2004-11-04 EA EA200600869A patent/EA011302B1/ru not_active IP Right Cessation
- 2004-11-04 JP JP2006539719A patent/JP4931597B2/ja active Active
- 2004-11-04 US US10/578,410 patent/US7638606B2/en active Active
- 2004-11-04 MX MXPA06004853A patent/MXPA06004853A/es active IP Right Grant
- 2004-11-04 AU AU2004290017A patent/AU2004290017B2/en not_active Ceased
- 2004-11-04 WO PCT/US2004/037242 patent/WO2005047331A2/en active Application Filing
- 2004-11-04 GE GEAP20049439A patent/GEP20104991B/en unknown
- 2004-11-04 NZ NZ547588A patent/NZ547588A/en not_active IP Right Cessation
- 2004-11-04 TW TW093133677A patent/TWI356064B/zh not_active IP Right Cessation
- 2004-11-04 ES ES04810551T patent/ES2383809T3/es active Active
- 2004-11-04 KR KR1020067008369A patent/KR101225463B1/ko not_active IP Right Cessation
-
2006
- 2006-04-26 IS IS8432A patent/IS8432A/is unknown
- 2006-04-27 EC EC2006006526A patent/ECSP066526A/es unknown
- 2006-04-28 MA MA28982A patent/MA28418B1/fr unknown
- 2006-04-28 NI NI200600098A patent/NI200600098A/es unknown
- 2006-05-01 IL IL175362A patent/IL175362A/en not_active IP Right Cessation
- 2006-05-05 TN TNP2006000128A patent/TNSN06128A1/en unknown
- 2006-05-11 CR CR8396A patent/CR8396A/es unknown
- 2006-05-12 NO NO20062148A patent/NO20062148L/no not_active Application Discontinuation
- 2006-06-06 ZA ZA200604605A patent/ZA200604605B/xx unknown
-
2009
- 2009-08-04 US US12/535,648 patent/US7872113B2/en active Active
-
2010
- 2010-12-10 US US12/965,564 patent/US20110081361A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062148L (no) | Antistoffer som binder interleukin-4-reseptor | |
DK1534335T3 (da) | FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf | |
ATE482722T1 (de) | Therapeutische verwendung von anti-cs1- antikörpern | |
DK1734995T3 (da) | Monoklonale antistoffer og hepatocyytvækstfaktor | |
PL401886A1 (pl) | Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal | |
MX2009003093A (es) | Composiciones y metodos relacionados con anticuerpos del receptor de glucagon. | |
IS7770A (is) | Hlutleysandi mótefni gegn GDF-8 og notkun theirra | |
DK1629011T3 (da) | Humane anti-humane-DC3-bindingsmolekyler | |
EA200702093A1 (ru) | Антитела-миметики glp-1 человека, композиции, способы и их применение | |
EA201070636A1 (ru) | Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения | |
ATE497392T1 (de) | Therapie mit anti-cd4-antikörpern und bestrahlung | |
EA202192090A1 (ru) | Антигенсвязывающие белки против гамма-цепи рецептора il2 | |
ATE342976T1 (de) | Cytokinrezeptor-kette | |
BR0315042A (pt) | Terapia para o tratamento de aterosclerose baseada em imunização passiva por peptìdeo | |
DK1411962T3 (da) | Terapi for pancreacancer med monoklonalt stof | |
ATE534902T1 (de) | Replikationsproteinn ciz1 | |
EP1808179A3 (en) | Use of HSP20 for promoting wound healing and/or reducing scar formation | |
DE50210279D1 (de) | Screeningverfahren mit bnpi und dnpi | |
DE502004012439D1 (de) | Medikament und verwendung zur tumortherapie | |
SE0202959D0 (sv) | Peptide-Base passive immunization therapy for treatment of atherosclerosis | |
ATE490981T1 (de) | Criptospezifische antikörper | |
TH126202A (th) | แอนติบอดีเพื่อการทำให้เป็นกลางต้าน-ngf ของมนุษย์ดังที่เป็นสารยับยั้งวิถี ngf แบบคัดสรร | |
CY1114835T1 (el) | Πληρη ανθρωπινα αντισωματα εναντι ανθρωπινου 4-1ββ (cd137) | |
WO2006110367A3 (en) | Methods and compositions for mycoplasma toxins | |
DK1340507T3 (da) | Anvendelse af et fibroblastvækstfaktor-bindingsprotein til behandling og diagnosticering af diabetiske sårhelingsforstyrrelser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |